Sundaram Senthil Vel 4
4 · Terns Pharmaceuticals, Inc. · Filed Feb 3, 2023
Insider Transaction Report
Form 4
Sundaram Senthil Vel
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2022-11-30$1.41/sh+3$4→ 7,659 total - Award
Stock Option (Right to Buy)
2023-02-01+900,000→ 900,000 totalExercise: $8.94Exp: 2033-01-31→ Common Stock (900,000 underlying)
Footnotes (2)
- [F1]Includes the purchase of 3 shares under the Terns Employee Stock Purchase Plan on November 30, 2022.
- [F2]25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.